Fig. 5: SARS-CoV-2 infected fused cortical-blood vessel organoids expressed β-amyloid plaques. | Cell Death Discovery

Fig. 5: SARS-CoV-2 infected fused cortical-blood vessel organoids expressed β-amyloid plaques.

From: Cortical-blood vessel assembloids exhibit Alzheimer’s disease phenotypes by activating glia after SARS-CoV-2 infection

Fig. 5

A Immunostaining of SARS-CoV-2 or mock infected fCBOs and COs for NP and Aβ. Scale bars = 100 μm. B Thioflavin-S staining of SARS-CoV-2 or mock infected fCBOs. Scale bars = 100 μm. C Concentrations of Aβ42 and Aβ40 quantified by ELISA and Aβ peptide 42/40 ratios in fCBOs before and after SARS-CoV-2 infection (n = 3). D Immunostaining of SARS-CoV-2 infected fCBOs for Aβ and 42-residue Aβ (Aβ42) or 40-residue Aβ (Aβ40). Cortical organoid region (left) and blood vessel organoid region (right). Scale bars = 100 μm. E Immunostaining of SARS-CoV-2 or mock infected BVOs for Aβ and Aβ40. Scale bars = 50 μm. F Western blot for β-amyloid precursor protein (APP), β-secretase (BACE1) and the loading control β-actin of SARS-CoV-2 or mock infected fCBOs and relative protein levels. (n = 3). G Immunostaining of SARS-CoV-2 or mock infected fCBOs for BACE1 and NP. Scale bars = 100 μm. H Concentrations of Aβ42 and Aβ40 quantified by ELISA and Aβ peptide 42/40 ratios in mock control, SARS-CoV-2 infected and DAPT treated fCBOs (n = 3). Values represent mean with individual data points plotted. Error bars are SEM of the mean. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired two-sided t-test.

Back to article page